Advice
Following a resubmission
levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy.
In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy achieved a greater reduction in partial seizure frequency than addition of placebo.
Download detailed advice85KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 394/07
- Indication:
- Adjunctive therapy in treatment of partial onset seizures with or without sedondary generalisation in children from 4 years of age with epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 11 February 2008